stockrow
Friday 6 November 2026
Export GRAL’s income statement to Excel — free account
GRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.
- Revenue
- +3.71%
- EPS
- +10.2%
- Free cash flow
- −24.9%
Quarter to September 2026, against a year earlier
127.85
8.72
+7.32%
Follow GRAL
Alert me
GRAIL, Inc. (GRAL) Net income
GRAIL, Inc.'s net income for fiscal 2025 was −$408.4M, compared with −$2.0B in fiscal 2024. Over the twelve months to 30 September 2026 it was −$406.2M. GRAIL, Inc. ranks 48th of 49 Diagnostics & Research companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$408.4M | — |
| FY2024 | −$2.0B | — |
| FY2023 | −$1.5B | — |
| FY2022 | −$5.4B | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$103.6M | — |
| Jun 2026 | −$110.2M | — |
| Mar 2026 | −$93.2M | — |
| Dec 2025 | −$99.2M | — |
| 11 more quarters | Free account |
Net income against peers
| Company | Net income |
|---|---|
| ICLR ICON PLC compare | $448.7M |
| QGEN QIAGEN N.V. compare | $409.3M |
| SHC Sotera Health Company compare | $173.5M |
| CDNA CareDx, Inc. compare | $128.6M |
| VCYT Veracyte, Inc. compare | $126.8M |
| BLLN BillionToOne, Inc. compare | $49.4M |
| RDNT RadNet, Inc. compare | $19.3M |
| ADPT Adaptive Biotechnologies Corporation compare | −$70.7M |
| GRAL GRAIL, Inc. | −$406.2M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on GRAL
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement